BridgeBio Oncology Therapeutics (BBOT) Change in Cash (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Change in Cash for 3 years, with the latest figure at -$321.0 million in Q1 2026.

• Quarterly Change in Cash fell 6826.19% year-over-year to -$321.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.4 million (up 9.02% YoY) and the FY2025 annual result came in at $342.8 million, up 1015.53% from the prior year.
• Change in Cash fell to -$321.0 million in Q1 2026 per BBOT's latest filing, from -$35.1 million in the prior quarter.
• Over five years, Change in Cash peaked at $378.9 million in Q3 2025 and troughed at -$321.0 million in Q1 2026.
• A 3-year average of $5.8 million and a median of $1.8 million in 2024 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2025 and 2026: Change in Cash surged 12476.56% in 2025, then slumped 6826.19% in 2026.
• Over 3 years, Change in Cash stood at $10.6 million in 2024, then sank by 431.54% to -$35.1 million in 2025, then tumbled by 815.81% to -$321.0 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$321.0 million, -$35.1 million, and $378.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.